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Abstract: This study tested Perftoran blood substitute and a association of Perftoran and Hypertonic Saline 
Solution for the use in haemorrhagic shock in rats. Four groups were made (n=10): P (Perftoran), PSH (Perftoran 
HSS), SH (HSS) and M (Control). Haemorrhagic shock was induced by controlled exsanguination until MAP 
decreased below 45 mmHg. Resuscitation therapy was initiated after 30’ of shock and was made with 0.9% NaCl 
solution in group M, 3.5% NaCl solution in group SH, Perftoran in group P and Perftoran associated with 2.9% 
NaCl solution in group PSH. Data analysis shows that both Perforan and PSH are efficient in oxygen delivering 




Exsanguination and haemorrhagic shock are the most frequent causes of death after 
acute trauma. Haemorrhagic shock is a critical imbalance between oxygen and nutrients 
delivery to the cell and the consume of those by the cell. In hipovolemia oxygen delivery to 
the tissues decreases, producing the breakdown of the oxidative metabolism and the activation 
of anaerobic metabolism. Anaerobic metabolism is associated with the increase of indicators 
for ischemia (lactic acid, base deficit). Those indicators reflect cellular oxygen need, proven 
as valid predictors for the probability of death after haemorrhagic shock in animals [1]. 
Bleeding control and compensation of the deficit in circulating blood volume represent 
the emergency treatment of haemorrhagic shock. This is done mainly by the use of  
asanguinous solutions (crystalloid and colloid). Those solutions provide volume replacement 
but do not provide oxygen transport. Dilution anemia is induced by asanguinous solutions 
and, to a certain degree, is compensated by an increase in cardiac output and arterial oxygen 
extraction. However, when hematocrit falls below critical values, these compensatory 
mechanisms become exhausted. Tissue hypoxia occurs then, even in the presence of 
normovolemia, and transfusion of red blood cells becomes indispensable to restore the 
oxygen transport capacity of blood. 
Blood transfusion may be a problem for veterinarians because of the large number of 
blood groups, lack of universal donors and absence of blood storage facilities for animals. In 
this cases, blood substitutes may be a useful treatment solution. Blood substitutes are oxygen-
carrying fluids that are designed to provide an alternative to the blood transfusion. 
Perfluorocarbons are a category of blood substitutes which rely on the ability of this 
substances to dissolve and transport oxygen. Perftoran is a perfluorocarbon emulsion made of 
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perfluorodecalin and perfluoromethylcyclohexylpiperidin that solves 7% vol. of oxygen [3, 
4]. 
The purpose of the present study was to investigate the effects of primary fluid 
resuscitation with Perftoran-Hypertonic Saline Solution association as compared with single 
administration of Perftoran, Hypertonic Saline Solution 3.5% and physiologic NaCl solution 
0.9% [5].  
 
MATERIAL AND METHODS 
 
Animals. Experiments were performed in 40 healthy adult Wistar rats, weighing 
between 280-360 g (mean 317.6 ± 17.8 g). All animals included in this study received care in 
compliance with “3R” principles of animal wellness. 
Animal preparation. Anesthetic induction and maintain were made with Xylazine 2% 
(7,5-10 mg/kg) and Ketamine 10% (60-
90 mg/kg) by intramuscular injection. 
Following anesthesia, rats were intubated 
with an adapted intravenous catheter with 
the help of the intubation device 
described by Ordodi et al. Rats were 
mechanically ventilated with 100% 
oxygen at a rate of 70 ventilations/minute 
and positive end expiratory pressure of 3 
cm H2O using the rat respirator described 
by the same author. A warming pad 
(Labovolt Prolab) was used to maintain 
core body temperature >37°C (98.6°F) 
[6, 7].  
The following probes and catheters 
were placed: ECG probes for recording of lead II, rectal thermometer probe, 24G catheter 
(VasoFix Certo, Braun Medical) in external carotid artery for mean arterial pressure (MAP) 
monitoring and blood withdraw. 
Carotid artery catheterization was made by sterno-mandibular incision of the skin, 
muscle retraction and isolation of the right carotid artery from the right artery-vein-nerve 
package. A 24G catheter was placed inside the artery. At 24G catheter a 3 way stopcock with 
arterial pressure monitoring line was attached (fig. 1).  
ECG lead II and MAP values were recorded on a computer using Digidata 1200 
acquisition system and Axoscope 10 acquisition software. 
Blood volume. Total blood volume was calculated with the help of the formula described 
by Lee and Blaufox [2]:  
Blood volume (ml) = 0.06 x Body Weight + 0.77 
Blood samples. Gas analysis arterial blood samples were taken in 2 ml syringe with 
lithium heparin. Arterial blood gases were determined using a GEM Premium 3000 blood gas 
analyzer. Hemoleucogram samples were taken in 500 µl Capiject EDTA microtainers 
(Terumo) and determined by impedance and flow cytometry with a Cell-Dyn 3700 device. 
Samples were collected before exsanguination (0 min, baseline), after haemorrhagic 
shock installation (30 min, shock) and 30 minutes after therapy administration (60 min, 
therapy).   
 
Fig. 1: Catheterized rat connected to pressure transducer 


























































Fig. 3:  pH. 
Experimental protocol. After completion of surgical preparation, a 20 minutes 
stabilization period was allowed before samples of blood were collected for baseline values. 
During this period ECG and MAP were permanently recorded. Mean arterial pressure was 
then reduced within 10 minutes to 45 mmHg by repeated withdrawals of blood and 
maintained at this value for 30 minutes. 
After 30 minutes of hipovolemia blood was collected for haemorrhagic shock values. 
For therapy, the volume of blood 
removed during exsanguination 
period was replaced in a randomized 
order by three times volume of NaCl 
0.9% solution (M or control group), 
31ml/kg NaCl 3.5% hypertonic 
solution (HSS group) , 20 ml/kg 
Perftoran blood substitute (Perftoran 
or P group) or 32 ml/kg from a 
mixed solution made of Perftoran 
and NaCl 2.9% in equal parts 
(Perftoran-HSS group). Exsanguinations, blood sampling and therapy were made through 
arterial catheter. 
Statistics. Statistical analysis was performed with Office Excel 2003 (Microsoft) and 
StatPlus 2005 (AnalystSoft). Obtained data were expressed as mean ± standard error. Statistic 
analysis was made using Man-Whitney test for compare inside the group and between the 
groups. Values of p<0.05 were considered statistically significant. 
Experiments were funded from CNCSIS grant TD-431/2007, contract 484/2007. 
   
 
RESULTS AND DISCUSIONS 
 
 Decreasing MAP (fig. 2) below 
45 mmHg required withdrawal of 1.95 ± 
0.06 mL/100g in group M, 2.00 ± 0.05 
mL/100g in group SH, 2.29 ± 0.15 
mL/100g in group P and 2.10 ± 0.15 
mL/100g in group PSH. Mean arterial 
pressure decreased after exanguination 
bellow 45 mmHg and was maintained at 
this level for 30 minutes.  
Primary resuscitation consisted in 
intra-arterial infusion of 5.25 ± 0.23 
mL/100g NaCl 0.9% in group M, 2.75 ± 
0.24 mL/100g NaCl 3.5% in group SH, 
3.33 ± 0.28 mL/100g Perftoran in group 
P and 3.50 ± 0.35 mL/100g Perftoran + 
NaCl 2.9% in group PSH. After 
resuscitation MAP increased to 59 mmHg 
in group M (0.9% NaCl solution), 60 
mmHg in group SH (3.5% NaCl), 94 
mmHg in Group P (Perftoran) and 83 
Table 1. Characteristics of Perftoran (after Maevsky and col., 




Emulsifiers (surfactants) Proxanol 268 
 Egg yolk phospholipids 
Total PFC content (% w/v) 20.0 
Average droplet diameter/µm 0.07 
pH 7.3 
Osmolarity/mOsm kg–1 300 
Viscosity/cP 2.3 
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mmHg in group PSH (Perftoran – HSS association) [8].   
 PH values (fig. 3) decreased after exanguination and continued to decrease after 
therapy in all groups. At the end of haemorrhagic shock period, pH decreased with 2.91% in 
group M, 1.33% in group SH, 2.5% in group P and 2.39% in group PSH. After therapy 
administration pH increased with 0.68% in 
group M and decreased with 1.57% in 
group SH, 0.43% in group P, 0.75% in 
group PSH. This values together with lactic 
acid and PCO2 values show that decrease of 
pH occurred because of lactic acidosis . 
Partial pressure of carbon dioxide 
from arterial blood dynamic (fig. 4) was 
similar to all groups. After hemorrhage 
decreased in all groups and after therapy 
administration PCO2 increased in all 
groups. Animals were ventilated with 
100%  oxygen at a constant rate of 66-72 
respirations/minute and variations did not 
occurred between stages of experiment. 
PCO2 values bellow normal were recorded 
because of 100% oxygen ventilation and 
not because of hyperventilation. Thus, the 
decrease of PCO2 values after hemorrhage 
was caused by a decrease in oxygen 
consume after decreased tissue perfusion. 
The increase of PCO2 values after therapy 
was caused by the reestablish of tissue 
perfusion and oxygen consume. This also 
explains why PCO2 values were higher in P 
and PSH groups compared to M and SH 
groups. The difference between P and PSH 
values is probably caused by the Perftoran 
dose, which was reduced to half in PSH group [9]. 
Partial O2 pressure (fig. 5) was in 
normal range for animals breathing 100% 
oxygen. PO2 slightly increased after 
hemorrhagic shock, but not significant. PO2 
values increased with 54.43 mmHg after 
Perftoran and with 62.75 mmHg after PSH 
administration. The PO2 values also 
increased in M and SH groups but the 
increase is much lower (21 mmHg in group 
M, 32.8 mmHg in group). 
Lactate values (fig. 6) increased after 
shock and decreased after therapy. In 
insufficient oxygen NADH cannot release 
the H+ and they build up in the cell. To prevent the rise in acidity, pyruvic acid accepts H+ 





















































Fig. 6: Lactate (mmol/L) 
 
Fig. 5: O2 partial pressure (mmHg) 
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Baseline values of base deficit (fig. 7) were 5,53±1,04 mmol/L in group M, 0,35±0,61 
mmol/L in group SH, 1,07±0,84 mmol/L in group P and 2,75±0,72 mmol/L in group PSH. 
This values indicate a slightly acidosis in group M. 
Base deficit increased at the end of 
hemorrhagic shock phase to 15,7±2,72 
mmol/L in group M, 10,52±1,06 mmol/L in 
group SH, 12,90±0,81 mmol/L in group P 
and at 15,23±1,11 mmol/L in group PSH, 
indicating severe acidosis. 
After therapy base deficit decreased to 
12,70±1,69 mmol/L in group M, increased 
to 11,08±1,61mmol/L in group SH, 
decreased to 8,29±1,16 mmol/L in group P 
and decreased to 12,10±2,73 mmol/L in 
group PSH. Showed results indicate that 
base deficit decreases most after Perftoran 
administration [9]. 
Hematocrit values (fig. 8) were similar 
in all groups and followed the same 
dynamic curve. Baseline hematocrit values 
were 37±2.65% in group M, 41±1.32% in 
group SH, 41.27±1.14% in group P, 
41.1±1.58% in group PSH. After 
hemorrhagic shock hematocrit decreased to 
29.33±2.03% in group M, 30±2% in group 
SH, 31.45±1.55% in group P and 
30.67±1.83% in group PSH. Therapy 
decreased hematocrit values further by 
dilutional effect: 23±3.16% in group M, 
22.6±1.5% in group SH, 25±1.09% in group 
P and 22.56±1.97% in group PSH. 
Hemoglobin values (fig. 9) also 
decreased together with hematocrit, 
following the same curve. 
Showed results indicate that after a 
loss of blood between 31.28±1.36 and 
41.7±6.31 % of blood volume, MAP 
decreases to critical values (below 45 
mmHg), hematocrit drops with 7.67 to 11% 
and hemoglobin concentration decreases 
with 3.1 to 3.9 g/dL. This decreases tissue 
perfusion and induces the change in cell 
metabolism to anaerobic. Because 
respiratory system is working well and 
animals were ventilated with 100% oxygen, 
but tissue perfusion is highly decreased and there is not enough hemoglobin to bind oxygen, 
partial pressure of oxygen in arterial blood remains unchanged and slightly increases. Oxygen 
accumulates in the blood but it cannot get entirely to the tissue. This decreases the oxygen 
 
























































Fig. 9. Hemoglobin concentration (g/dL) 
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consume which leads to a decrease in carbon dioxide production. To compensate acidosis, 
lactate accumulates in the blood. PH decreases, being more acid and the base deficit highly 
increases. 
Fluid administration of Perftoran and PSH increases MAP, decreases hematocrit and 
hemoglobin levels, inducing dilution anemia. Although dilution anemia occurred, 
oxygenation was efficient as showed by the increase of PCO2, MAP and PO2 and decrease of 




 Perftoran increases oxygenation and restores blood pressure almost to normal values, disregarding 
the decrease of hematocrit and hemoglobin; 
 Perftoran associated with NaCl 2.9% solution has the same effect, but in this dose is not so 
efficient as Perftoran. A increase in Perftoran dose together with a increase of NaCl concentration 
to 7% will probably be more efficient and follows to be tested; 
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